In other areas within this field, models have already been developed to validate treatment selection algorithm for SGLT2 inhibitor and DPP‐4 inhibitor therapies in type 2 diabetes [39] However, the use of predictive models based on various clinical and socio‐economic variables for studying optimal glycaemic control in diabetes, assessed by isCGM glucose metrics, remains unexplored. This evidence concerns the gene SLC5A2 and diabetes mellitus.